Seeking Alpha

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a ...
Benzinga.com

Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says

Tempus AI is a healthcare technology company that utilizes artificial intelligence technology to collect and analyze molecular, clinical, and genomic data. It collects clinical and genomic databases ...
Crain's Chicago Business

Tempus gets FDA OK for software to detect cardiac issue

Tempus AI has gained clearance for software that uses artificial intelligence to identify patients who may have the cardiovascular condition of low left ventricular ejection fraction, or LVEF. The ...
Nasdaq

A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost ...
Insider Monkey

Tempus AI (TEM) Secures FDA Clearance for AI-Powered Heart Monitoring Software

Tempus AI, Inc. (NASDAQ:TEM) is one of the top 10 medical AI companies to buy according to analysts. On July 16, the company confirmed that it had received clearance from the US Food and Drug ...
Business Wire

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using ...
Benzinga.com

Tempus AI Stock Is Surging Today: What Investors Are Watching

Tempus AI Inc (NASDAQ:TEM) shares are moving higher Monday after the company introduced a new program to monitor immunotherapy response for patients with advanced cancer. What Happened: Tempus has ...
Hosted on MSN

Tempus AI: Volatility Equates to Opportunity in AI Leader

Tempus AI’s (NASDAQ: TEM) stock price pulled back in early November following its Q3 release, aligning with broader market action and opening a buying opportunity for investors. The primary concern is ...
ascopubs.org

TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment.

Using machine learning for targeted advance care planning (ACP) conversations in patients with cancer: A quality improvement initiative.
Seeking Alpha

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects ...
Joplin Globe

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will ...